New Sjӧgren's syndrome therapies may target BAFF recep

New Sjӧgren's syndrome therapies may target BAFF receptors, CD40

DESTIN, Fla. — Multiple potentially new therapies promise to improve the management of patients with Sjgren’s syndrome, according to a speaker at the 2023 Congress of Clinical Rheumatology meeting.These advancements follow years of researchers struggling to repurpose existing drugs to fit the needs of patients with the disease.

Related Keywords

Florida , United States , Shenaz Bagha , Byerich Martin , Otsuka Visterra , Saras Mccoy , Sara Mccoy , Novartis , University Of Wisconsin School Medicine , Clinical Rheumatology East , Clinical Rheumatology , Wisconsin School ,

© 2025 Vimarsana